The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study

References

• Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84(3):413–428. doi:10.1016/S0163-7258(99)00045-5
   PubMed Web of Science ®Google Scholar
• Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation. 2004;110(9):1061–1068. doi:10.1161/01.CIR.0000140261.58966.A4
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H, et al.; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet. 368;2006:1155–1163. doi:10.1016/S0140-6736(06)69472-5
   PubMed Web of Science ®Google Scholar
• Yokomichi H, Nagai A, Hirata M, et al. Statin use and all-cause and cancer mortality: bioBank Japan cohort. J Epidemiol. 2017;27(3S):S84–S91. doi:10.1016/j.je.2016.12.011
   PubMedGoogle Scholar
• Di Bello E, Zwergel C, Mai A, Valente S. The innovative potential of statins in cancer: new targets for new therapies. Front Chem. 2020;8:516. doi:10.3389/fchem.2020.00516
   PubMed Web of Science ®Google Scholar
• Tsubaki M, Fujiwara D, Takeda T. The sensitivity of head and neck carcinoma cells to statins is related to the expression of their Ras expression status, and statin-induced apoptosis is mediated via suppression of the Ras/ERK and Ras/mTOR pathways. Clin Exp Pharmacol Physiol. 2017;44(2):222–234. doi:10.1111/1440-1681.12690
   PubMed Web of Science ®Google Scholar
• Saito Y. Pitavastatin: an overview. Atheroscler Suppl. 2011;12(3):271–276. doi:10.1016/S1567-5688(11)70886-8
   PubMed Web of Science ®Google Scholar
• Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag. 2009;5:921–936. doi:10.2147/VHRM.S5551
   PubMedGoogle Scholar
• Xu B, Muramatsu T, Inazawa J. Suppression of MET signaling mediated by pitavastatin and capmatinib inhibits oral and esophageal cancer cell growth. Mol Cancer Res. 2020;19(4):585–597.
   PubMed Web of Science ®Google Scholar
• Sever PS, Dalhoff B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet. 2003;361(9364):1149–1158. doi:10.1016/S0140-6736(03)12948-0
   PubMed Web of Science ®Google Scholar
• Moroi M, Nagayama D, Hara F, et al. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol. 2020;305:139–146. doi:10.1016/j.ijcard.2020.01.006
   PubMed Web of Science ®Google Scholar
• Nagayama D, Saiki A, Watanabe Y, et al. Prevention of cardiovascular events with pitavastatin is associated with increased serum lipoprotein lipase mass level: subgroup analysis of the TOHO-LIP. J Atheroscler Thromb. 2021. doi:10.5551/jat.62141
   Web of Science ®Google Scholar
• Nilsson-Ehle PA, Garfinkel AS, Schotz MC. Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem. 1991;49:667–693. doi:10.1146/annurev.bi.49.070180.003315
   Google Scholar
• Ohira M, Endo K, Saiki A, et al. Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase. Metabolism. 2012;61(10):1452–1460. doi:10.1016/j.metabol.2012.03.010
   PubMed Web of Science ®Google Scholar
• Din FVN, Valanciute A, Houde VP, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142(7):1504–1515.e3. doi:10.1053/j.gastro.2012.02.050
   PubMed Web of Science ®Google Scholar
• Yue W, Yang CS, DiPaola RS, Tan X-L. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res. 2014;7(4):388–397. doi:10.1158/1940-6207.CAPR-13-0337
   PubMed Web of Science ®Google Scholar
• Chou CC, Lee KH, Lai IL, et al. AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Res. 2014;74(17):4783–4795. doi:10.1158/0008-5472.CAN-14-0135
   PubMed Web of Science ®Google Scholar
• Okubo K, Isono M, Miyai K, Asano T, Sato A. Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells. Cancer Sci. 2020;111(1):112–126. doi:10.1111/cas.14225
   PubMed Web of Science ®Google Scholar
• Lee N, Pun N, Jang W, Bae J, Jeong C. Pitavastatin induces apoptosis in oral squamous cell carcinoma through activation of FOXO3a. J Cell Mol Med. 2020;24(12):7055–7066. doi:10.1111/jcmm.15389
   PubMed Web of Science ®Google Scholar
• Jiang P, Mukthavaram R, Chao Y, et al. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer. 2014;111(8):1562–1571. doi:10.1038/bjc.2014.431
   PubMed Web of Science ®Google Scholar
• You HY, Zhang WJ, Xie XM, Zheng ZH, Zhu HL, Jiang FZ. Pitavastatin suppressed liver cancer cells in vitro and in vivo. Onco Targets Ther. 2016;9:5383–5388. doi:10.2147/OTT.S106906
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Zheng SH, Yang WG, Yang C, Yuan WT. Targeting colon cancer stem cells with novel blood cholesterol drug pitavastatin. Eur Rev Med Pharmacol Sci. 2017;21:1226–1233.
   PubMed Web of Science ®Google Scholar
• de Wolf E, Abdullah MI, Jones SM, et al. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Sci Rep. 2017;7(1):5410. doi:10.1038/s41598-017-05595-4
   PubMedGoogle Scholar
• Villarino N, Signaevskaia L, van Niekerk J, et al. A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer. Oncotarget. 2017;8(32):53154–53167. doi:10.18632/oncotarget.18587
   PubMedGoogle Scholar
• Wang L, Wang Y, Chen A, et al. Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway. FASEB J. 2019;33(12):13710–13721. doi:10.1096/fj.201901388R
   PubMed Web of Science ®Google Scholar
• Fujino M, Miura S, Matsuo Y, Tanigawa H, Kawamura A, Saku K. Pitavastatin-induced downregulation of CCR2 and CCR5 in monocytes is associated with the arrest of cell-cycle in S phase. Atherosclerosis. 2006;187(2):301–308. doi:10.1016/j.atherosclerosis.2005.10.008
   PubMed Web of Science ®Google Scholar
• Otahal A, Aydemir D, Tomasich E, Minichsdorfer C. Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines. Sci Rep. 2020;10(1):959. doi:10.1038/s41598-020-57707-2
   PubMed Web of Science ®Google Scholar
• Jiao Z, Cai H, Long Y, et al. Statin-induced GGPP depletion blocks macropinocytosis and starves cells with oncogenic defects. Proc Natl Acad Sci U S A. 2020;117(8):4158–4168. doi:10.1073/pnas.1917938117
   PubMed Web of Science ®Google Scholar